Phase I oncology trials: risks and benefits vary by trial type

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2005年 / 1042卷 / 1期
关键词：
Public Health; Toxic Event; Cancer Therapy; Chemotherapeutic Agent; Stable Disease;
D O I：
10.2165/00128415-200510420-00010
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5 / 5
相关论文
共 50 条
  • [31] New adaptive method for phase I trials in oncology
    Meille, C.
    Gentet, J. C.
    Barbolosi, D.
    Andre, N.
    Doz, F.
    Iliadis, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (06) : 873 - 881
  • [32] Redefining the primary objective of phase I oncology trials
    Mark J. Ratain
    Nature Reviews Clinical Oncology, 2014, 11 : 503 - 504
  • [33] The importance of phase I/II trials in pediatric oncology
    MacArthur, CA
    Vietti, T
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (01) : 33 - 35
  • [34] Design of phase I clinical trials in radiation oncology
    Belderbos, JSA
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S136 - S136
  • [35] A third of phase I oncology trials remain unreported
    Tamsin Osborne
    Nature Clinical Practice Urology, 2005, 2 (12): : 580 - 580
  • [36] Increasing complexity in oncology phase I clinical trials
    Laeeq Malik
    David Lu
    Investigational New Drugs, 2019, 37 : 519 - 523
  • [37] Phase I clinical trials in oncology: Ethical issues
    Goldwasser, F
    THERAPIE, 2004, 59 (04): : 431 - 433
  • [38] Exploring the Benefits and Risks of AI in Oncology
    James, Ted A.
    ONCOLOGY-NEW YORK, 2024, 38 (05):
  • [39] Hospice benefits and phase I cancer trials - In response
    Byock, I
    Miles, SH
    ANNALS OF INTERNAL MEDICINE, 2004, 140 (01) : 71 - 71
  • [40] Trends in the risks and benefits to patients with cancer in phase 1 clinical trials
    Ross, S
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (07): : 795 - 795
12345